Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.50 |
| ▸ | VEGFA | P15692 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452725 | 1.00 | EGLN1 (0.50) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL24257789 | 0.89 | PPID (0.42) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL30452447 | 0.89 | PPID (0.42) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL30452524 | 0.88 | KDM4E (0.46) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL24257788 | 0.88 | KDM4E (0.46) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL24257567 | 0.87 | EGLN1 (0.65) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL30452729 | 0.87 | EGLN1 (0.41) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL24257795 | 0.87 | EGLN1 (0.41) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL24257697 | 0.85 | EGLN1 (0.50) | EGLN1FTOEGLN2GAARAB9A | |
| SCHEMBL24257793 | 0.85 | GAA (0.51) | EGLN1EGLN3VEGFAFLT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | EGLN1 19/4885EGLN3 2/4885FTO 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.